Peptides referenced here are research chemicals. Their use outside of approved clinical settings is not endorsed.
A clinician I spoke with mentioned that a 2023 case report described a patient losing something like 30-50% of excess body weight on a triple agonist in a trial setting, but the path to prescribing that same drug in a clinic just got longer. In late 2024, the FDA issued draft guidance (FDA 2024) that directly addresses the development of drugs with multiple pharmacologically active components, including fixed-dose combinations and single molecules that hit more than one target. For retatrutide, the triple agonist that activates GLP-1, GIP, and glucagon receptors, this means the regulatory finish line has moved.
The Guidance: What Changed
The draft document, titled "Combinations of Drugs and Biologics with More Than One Pharmacologically Active Component," outlines a framework for demonstrating that each component contributes to the overall effect. For a triple agonist like retatrutide, this is not a trivial ask. The agency wants sponsors to show that the three-pronged mechanism is better than any dual-agonist or single-agonist comparator. That could require multi-arm trials comparing retatrutide to a GLP-1/GIP dual agonist like tirzepatide, and possibly to a GLP-1 monoagonist like semaglutide.
The guidance also stresses the need for dose-response data for each component. For a single molecule that hits three receptors, teasing apart those contributions is complex. Pharmacodynamic markers and receptor occupancy data will likely be required. The FDA is essentially saying: prove that the glucagon agonism adds something meaningful beyond what GLP-1 and GIP already deliver.
Retatrutide's Clinical Position
Retatrutide has generated excitement because Phase 2 data (Jastreboff 2023) showed weight loss in the neighbourhood of 24% at 48 weeks, a figure that surpasses tirzepatide's roughly 21% in similar time frames. But the new guidance raises the bar for the Phase 3 program, which is already underway. Eli Lilly, the sponsor, will need to navigate these requirements carefully. The company has not publicly detailed how it will address the component contribution question, but the guidance will almost certainly shape the design of ongoing and future trials.
For the broader GLP-1 market, this guidance signals that the FDA is not going to let multi-agonist drugs slide through on weight loss alone. The agency wants mechanistic clarity. This could slow down the development of other triple agonists and even some dual agonists that have not yet filed.
Compounding and the Gray Market
While retatrutide is not yet approved, the compounding world has already taken notice. Some compounding pharmacies and research chemical suppliers have begun offering retatrutide as a "research peptide," often alongside other compounds like AOD-9604, a fragment of human growth hormone that has been studied for fat loss. AOD-9604 itself has a checkered regulatory history, with an FDA rejection for obesity in 2017 due to lack of efficacy. Yet it persists in the gray market, sometimes stacked with GHRP-6 or other peptides like Epitalon and Melanotan II.
The new guidance does not directly address compounding, but it reinforces the divide between approved drugs and unapproved substances. As retatrutide moves through the regulatory process, the availability of unregulated versions raises safety concerns. The FDA has already warned about compounded semaglutide and tirzepatide, and a similar pattern could emerge with retatrutide if demand spikes before approval.
Who's Affected
The guidance affects a range of stakeholders:
- Pharmaceutical companies developing multi-agonist drugs. Trial costs will rise, and timelines may extend. Smaller biotechs without deep pockets could struggle to meet the new requirements.
- Clinicians and researchers who are watching the triple agonist space. The evidence bar for new drugs will be higher, which could mean fewer options in the near term but more confidence in those that do reach the market.
- Patients seeking next-generation obesity treatments. The wait for a triple agonist might be longer than anticipated, which could push some toward unregulated alternatives.
- Compounding pharmacies and peptide suppliers who may see increased demand for research chemicals like retatrutide, AOD-9604, and related peptides. The regulatory risk for these entities is also rising as the FDA increases scrutiny of compounded GLP-1s.
What the Guidance Means for the Triple Agonist Class
The FDA's move is not entirely surprising. The agency has been signaling for years that it wants more rigorous evidence for combination products. In 2023, it issued a separate guidance on fixed-dose combinations that touched on similar themes. The new document, however, is more explicit about multi-target single molecules, which are becoming more common in metabolic disease.
For retatrutide, the guidance could mean that the Phase 3 program will need to include a tirzepatide arm, which would be a massive undertaking. Tirzepatide is already approved for type 2 diabetes and obesity, so a head-to-head trial would be a direct comparison of a dual agonist and a triple agonist. Such a trial would be expensive and time-consuming, but it would also provide the kind of data the FDA now seems to want.
There is also the question of safety. Glucagon agonism has been associated with hyperglycemia in some contexts, and the FDA will want to see that the benefit-risk profile is favorable. The guidance emphasizes that each component's safety contribution must be characterized. This could mean larger safety databases and longer follow-up.
The AOD-9604 Connection
AOD-9604 is often mentioned in the same breath as retatrutide in online forums, but the two are worlds apart in terms of regulatory status. AOD-9604 is a peptide fragment that was once investigated by Metabolic Pharmaceuticals for obesity. The FDA's rejection of the drug in 2017 was based on a lack of efficacy in Phase 2b trials. Despite this, it is still sold as a research chemical and sometimes used in combination with other peptides like GHRP-6, which stimulates growth hormone release.
The persistence of AOD-9604 in the gray market highlights a broader issue: as the GLP-1 market expands, so does the market for unapproved peptides that promise similar benefits. The new FDA guidance does not address these compounds directly, but it does set a higher standard for approved drugs, which could widen the gap between what is available by prescription and what is sold online.
What to Watch Next
Several developments will shape the triple agonist landscape in the coming months:
- Eli Lilly's response to the guidance. The company may provide updates on its Phase 3 program design, including whether it will include a tirzepatide comparator arm.
- FDA's finalization of the guidance. The draft is open for comment, and the final version could include changes based on industry feedback. Companies will be watching closely for any softening of the component contribution requirement.
- Enforcement actions against compounded retatrutide. If the FDA sees a surge in adverse events linked to unapproved retatrutide, it could issue warning letters or take other enforcement steps.
- Emerging data from other triple agonists. Several other companies have triple agonists in early development. Their progress will be influenced by the new regulatory environment.
The triple agonist field is at a crossroads. The science is promising, but the regulatory path is steeper than it was a year ago. For retatrutide, the next 12 to 18 months will be critical in determining whether it can clear the new hurdles and reach the market.